Indivior Inc. v. Actavis Laboratories UT, Inc.
1:16-cv-01009
Overview
Parties
Defendant
Actavis Laboratories UT, Inc. Operating Company
Represented By
2 Attorneys ListedPhillips, Goldman, McLaughlin & Hall, P.A.
Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Plaintiff
MonoSol Rx. LLC Operating Company
Represented By
3 Attorneys ListedWomble Bond Dickinson (US) LLP
1313 North Market Street, Suite 1200
Womble Bond Dickinson (US) LLP
1313 North Market Street, Suite 1200
Womble Bond Dickinson (US) LLP
1313 North Market Street, Suite 1200
Indivior UK Limited NPE (University / Research)
Represented By
3 Attorneys ListedWomble Bond Dickinson (US) LLP
1313 North Market Street, Suite 1200
Womble Bond Dickinson (US) LLP
1313 North Market Street, Suite 1200
Womble Bond Dickinson (US) LLP
1313 North Market Street, Suite 1200
Indivior Inc. Operating Company
Represented By
3 Attorneys ListedWomble Bond Dickinson (US) LLP
1313 North Market Street, Suite 1200
Womble Bond Dickinson (US) LLP
1313 North Market Street, Suite 1200
Womble Bond Dickinson (US) LLP
1313 North Market Street, Suite 1200
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 20 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 8,475,832 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 16,151,046 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 3,031,445 B1 | European Counterpart (EP) | View Official Patent → |
| π¨π¦ Canada | CA 2770180 A | Canada Counterpart | View Official Patent → |
| π PCT International (WIPO) | WO 2011017483 A2 | PCT World Application | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 10,740,493 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 2,461,795 B2 | European Counterpart (EP) | View Official Patent → |
| π¨π³ China | CN 2010800418 | China Counterpart | View Official Patent → |
| π¨π³ China | CN 102548535 B | China Counterpart | View Official Patent → |
| π°π· South Korea | KR 1020127006 | South Korea Counterpart | View Official Patent → |
| π°π· South Korea | KR 101699321 B1 | South Korea Counterpart | View Official Patent → |
| π―π΅ Japan | JP 2012523937 A | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 5819827 B2 | Japan Counterpart | View Official Patent → |
| πΊπΈ United States | US 2013028148 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2014000521 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8475832
Sublingual and buccal film compositions
|
Filed: 2009-08-07
Issued: 2013-07-02
|
Active (3.3 yrs remaining)
+231d PTA
Expires: 2030-03-26
|
|
|
US8017150
Polyethylene oxide-based films and drug delivery systems made therefrom
|
Filed: 2008-04-22
Issued: 2011-09-13
|
Expired (Term Ended)
Expires: 2023-10-10
|
|
|
US8603514
Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
|
Filed: 2007-07-10
Issued: 2013-12-10
|
Expired (Term Ended)
Expires: 2024-04-03
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+231 days) / Cellect Scrutiny β Over 231 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).